Evidence map›Paper›PMID 34528295›Full record

ArticleJournal of clinical laboratory analysis2021

The role of BDNF exon I region methylation in the treatment of depression with sertraline and its clinical diagnostic value.

Yuhua Xing, Ting Sun, Guangxue Li, Guoan Xu, Jia Cheng, Shugui Gao

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical laboratory analysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Methylation ofFrontiers in integrative neuroscience · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yuhua XingDepartment of Affective Disorder, Ningbo Kangning Hospital, Ningbo, Zhejiang, China.
Ting SunSchool of Medicine, Ningbo University, Ningbo, Zhejiang, China.
Guangxue LiDepartment of Affective Disorder, Ningbo Kangning Hospital, Ningbo, Zhejiang, China.
Guoan XuDepartment of Affective Disorder, Ningbo Kangning Hospital, Ningbo, Zhejiang, China.
Jia ChengDepartment of Affective Disorder, Ningbo Kangning Hospital, Ningbo, Zhejiang, China.ORCID https://orcid.org/0000-0003-3116-4035
Shugui GaoDepartment of Affective Disorder, Ningbo Kangning Hospital, Ningbo, Zhejiang, China.
Ningbo Kangning Hospital · CNNingbo University · CN

Funding

Life and Health Technology Innovation Team Fund of Ningbo 2015C110026Natural Science Foundation of Ningbo 2013A610249Natural Science Foundation of Ningbo 2015A610196Natural Science Foundation of Zhejiang Province LY21H090003Zhejiang Provincial Medical Technology Project 2015KYB351Zhejiang Provincial Medical Technology Project 2019KY628
6 · The paper itself

Abstract

backgroundBrain-derived neurotrophic factor (BDNF) is considered to be one of the best candidate genes for depression. However, whether sertraline treatment affects the methylation level of this gene remains unknown.

methodsFifty-three patients with depression and 51 healthy controls were included in the study. The methylation level of BDNF exon I was determined in blood samples from these subjects. The Hamilton Depression Scale was used to evaluate the depression status of patients. Single nucleotide polymorphism detection was used for genotyping, and a receiver operating characteristic (ROC) curve was used to evaluate the predictive value of the methylation level of this locus in patients with depression.

resultsThere was a significant difference in the methylation level of BDNF exon I between the control and depression groups. No effect of sertraline monotherapy on BDNF methylation was found in subjects with depression. Moreover, no interaction was found between BDNF genotype and the per cent methylation of BDNF exon I. However, methylation at this site was positively correlated with diurnal variation and retardation scores. Blood homocysteine concentrations were significantly reduced by sertraline treatment. No influence of genotype on serum BDNF concentration was found in subjects with depression. The ROC curve showed that methylation of BDNF exon I may be used to distinguish patients from healthy people, to a certain extent.

conclusionMethylation of BDNF exon I may be used as a biomarker of depression and may be a therapeutic target for previously untreated depression.

Indexed as

Brain-Derived Neurotrophic FactorDepressionAdolescentAdultAgedAntidepressive AgentsBiomarkersCase-Control StudiesDNA MethylationExonsFemaleHumansMaleMiddle AgedPolymorphism, Single NucleotideROC CurveAntidepressive AgentsBDNF protein, humanBiomarkersBrain-Derived Neurotrophic FactorSertraline5-hydroxytryptamineBDNFdepressiongene methylationsertraline

Identifiers

PMID34528295
PMCPMC8605126
OpenAlexW3200422907

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.